期刊文献+

白细胞介素10检测对乳腺癌患者预后的评估价值

The valuation value of interleukin-10 for the prognosis of breast cancer patients
下载PDF
导出
摘要 目的:探究白细胞介素10(IL-10)检测对乳腺癌患者预后的评估价值。方法:2018年8月-2019年5月收治乳腺癌患者86例,根据化疗疗效分为有效组50例和无效组36例。比较两组患者化疗前后血清IL-10水平。结果:有效组化疗后血清IL-10水平低于无效组,差异有统计学意义(P<0.05)。结论:血清IL-10检测对乳腺癌患者预后的评估具有一定价值,降低血清IL-10水平可能改善预后效果。 Objective:To explore the valuation value of interleukin-10 for the prognosis of breast cancer patients.Methods:From August 2018 to May 2019,86 breast cancer patients were selected.According to the chemotherapy effect,they were divided into the effective group(50 cases)and the ineffective group(36 cases).We compared the serum IL-10 levels of the two groups before and after treatment.Results:In the effective group,the level of serum IL-10 after chemotherapy was lower than that in the ineffective group,the difference was statistically significant(P<0.05).Conclusion:The detection of serum IL-10 has a certain value in the evaluation of prognosis of breast cancer patients,lowering the level of serum IL-10 may improve the prognosis.
作者 窦艳 邱鹏 王丽 刘晓丽 庞文帅 Dou Yan;Qiu Peng;Wang Li;Liu Xiaoli;Pang Wenshuai(The People's Hospital of Xingtai City,Hebei Xingtai 054000)
机构地区 邢台市人民医院
出处 《中国社区医师》 2020年第10期122-122,124,共2页 Chinese Community Doctors
基金 邢台市科技计划项目(项目编号:2018zc147).
关键词 乳腺癌 白细胞介素10 新辅助化疗 预后 Breast cancer Interleukin10 Neoadjuvant chemotherapy Prognosis
  • 相关文献

参考文献3

二级参考文献25

  • 1毛秋粉,尹雅芙,刘浩,李娜,李雪娜,周久茂,李亚明.乳腺癌患者化疗后认知功能障碍的研究现状[J].中华临床医师杂志(电子版),2011,5(15):4462-4464. 被引量:8
  • 2梁文波,张学梅,宋旦旨.西黄丸含药血清对人乳腺癌细胞生长的影响[J].时珍国医国药,2007,18(6):1371-1372. 被引量:17
  • 3Goldhirsch A,Wood WC,Coates AS. Strategies for subtypes--dealing with the diversity of breast cancer:highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J].{H}ANNALS OF ONCOLOGY,2011,(8):1736-1747.
  • 4Hammond ME,Hayes DF,Dowsett M. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version)[J].{H}ARCHIVES OF PATHOLOGY AND LABORATORY MEDICINE,2010,(7):e48-e72.
  • 5Wolff AC,Hammond ME,Schwartz JN. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[J].{H}ARCHIVES OF PATHOLOGY AND LABORATORY MEDICINE,2007,(1):18-43.
  • 6Cheang MC,Chia SK,Voduc D. Ki67 index,HER2status,and prognosis of patients with luminal b breast cancer[J].{H}JOURNAL OF THE NATIONAL CANCER INSTITUTE,2009,(10):736-750.
  • 7Kay E,O'Grady A,Morgan JM. Use of tissue microarray for interlaboratory validation of HER2 immunocytochemical and FISH testing[J].{H}Journal of Clinical Pathology,2004,(11):1140-1144.
  • 8Edge SB,Compton CC. The American Joint Committee on Cancer:the 7th edition of the AJCC cancer staging manual and the future ofTNM[J].{H}ANNALS OF SURGICAL ONCOLOGY,2010,(6):1471-1474.
  • 9Tavassoli FA,Devilee P,World Health Organization. Pathology and genetics of tumours of the breast and female genital organs[M].New York:WHO Publications Center,2003.
  • 10Perou CM,S(o)rlie T,Eisen MB. Molecular portraits of human breast tumours[J].{H}NATURE,2000,(6797):747-752.

共引文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部